Gursoy, P. Et Al. 2022. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.. Journal of cancer research and clinical oncology .

Gursoy, P., Tatli, A. M., Erdem, D., Goker, E., Celik, E., Demirci, N. S., ... Sakin, A.(2022). Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.. Journal of cancer research and clinical oncology .

Gursoy, Pınar Et Al. "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.," Journal of cancer research and clinical oncology , 2022

Gursoy, Pınar Et Al. "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.." Journal of cancer research and clinical oncology , 2022

Gursoy, P. Et Al. (2022) . "Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.." Journal of cancer research and clinical oncology .

@article{article, author={Pınar Gursoy Et Al. }, title={Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.}, journal={Journal of cancer research and clinical oncology}, year=2022}